Hemophilia Market Size To Hit USD 24.2 Billion By 2032, Driven By Advancements In Gene Therapy And Innovative Treatment Solutions – SNS Insider

(MENAFN- GlobeNewsWire - Nasdaq) Rising Prevalence of Hemophilia, Increasing Adoption of Recombinant Therapies, and Breakthroughs in Gene Therapy Propel Market Growth.

Pune, March 12, 2025 (GLOBE NEWSWIRE) -- Hemophilia Market Size & Growth Analysis:

“According to SNS Insider, the Hemophilia Market was valued at USD 13.7 billion in 2023 and is projected to reach USD 24.2 billion by 2032, growing at a CAGR of 6.5% over the forecast period 2024-2032.”

The global hemophilia market is growing rapidly, supported by ongoing advancements in treatment approaches such as gene therapy, extended half-life clotting factors, and prophylaxis. Enhanced awareness, early detection, and improved access to medical care have increased significantly and added to the market growth. The increasing use of recombinant therapies and non-factor therapies also is changing the face of managing hemophilia by providing greater efficacy and lower treatment burden.

Get a Sample Report of Hemophilia Market@

The need for new and durable treatment methods is increasing, especially with the advent of gene therapy, which promises to offer a single solution for hemophilia patients. Moreover, government support, strategic partnerships, and enhanced research and development funding are driving market growth. As pharmaceutical firms concentrate on creating new therapeutics and building their portfolios, the hemophilia market is anticipated to experience a vibrant change in treatment paradigms during the forecast period.

Major Players Analysis Listed in this Report are:

• Pfizer Inc. (Hympavzi, Beqvez)
• Novo Nordisk A/S (Alhemo, NovoEight)
• BioMarin Pharmaceutical Inc. (Roctavian)
• CSL Behring (Hemlibra, Idelvion)
• Swedish Orphan Biovitrum AB (Sobi) (Elocta, Alprolix)
• Sanofi S.A. (Efanesoctocog alfa, Alprolix)
• Roche Holding AG (Hemlibra)
• Takeda Pharmaceutical Company Limited (Advate, Adynovate)
• Octapharma AG (Nuwiq, Wilate)
• Grifols S.A. (Alphanate, Alphanine SD)

Hemophilia Market Report Scope

Report Attributes	Details
Market Size in 2023	US$ 13.7 Billion
Market Size by 2032	US$ 24.2 Billion
CAGR	CAGR of 6.5% From 2024 to 2032
Base Year	2023
Forecast Period	2024-2032
Historical Data	2020-2022
Key Regional Coverage	North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East]), Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America)

Segment Analysis

By Type:

Hemophilia A is the market leader with the highest market share of 73% in 2023, owing to its higher prevalence than other forms of hemophilia. This has created a huge demand for factor VIII replacement therapy, which is still the preferred treatment. The growth in availability of recombinant and extended half-life therapies also speaks in favor of Hemophilia A's market leadership.

The most rapidly expanding category is Hemophilia B, spurred by innovation in gene therapy, which promises long-term therapeutic benefit. As new gene therapies for hemophilia B have received approval, patient adoption rates will explode, cutting down on the need for recurrent clotting factor infusions.

By Treatment:

Prophylaxis treatment was 47% of the market share in 2023 because it is highly recommended to avoid spontaneous bleeding and permanent complications. Prophylactic treatment is now the preferred method for treating hemophilia, greatly enhancing patient quality and decreasing the rate of hospital visits.

The most rapidly expanding treatment segment is on-demand therapy because it allows patients to take treatment only at the time of bleeding. It is becoming popular, especially in emerging economies where prophylaxis treatment is not as easily accessible due to high costs.

By Therapy:

Factor replacement therapy dominated the hemophilia market and accounted for 60% of the overall market share in 2023. This established treatment continues to be a mainstay for hemophilia management, with the growth of the market influenced by developments in recombinant clotting factors. The sustained use of factor replacement therapy testifies to its ability to prevent and manage bleeding complications.

The most rapidly expanding category is gene therapy, which gained a great deal of pace with recent product approvals and encouraging clinical trial outcomes. Gene therapy presents a curative option in that it deals with the underlying genetic defect responsible for hemophilia, thus reducing or even avoiding the need for frequent clotting factor infusions.

By Distribution Channel:

Specialty pharmacies possessed the highest market share of 62% during 2023 due to their ability to manage complicated hemophilia therapies. They are vital to delivering specialized services, managing adherence to medications, and providing support programs for patients. Increasing dependency on specialty pharmacies for the treatment of hemophilia has also enhanced their market positioning.

The most rapidly expanding distribution channel is hospital pharmacies, driven by the growing formation of hospital-based infusion centers and integrated care units. With further expansion of hospital hemophilia treatment services, demand for in-hospital pharmaceutical care is likely to increase substantially.

Need any customization research on Hemophilia Market, Enquire Now@

Hemophilia Market Segmentation

By Type

• Hemophilia A
• Hemophilia B
• Others

By Treatment Type

• On-demand
• Cure
• Prophylaxis

By Distribution Channel

• Hospital Pharmacies
• Specialty Pharmacies

By Therapy

• Factor Replacement Therapy
  • Plasma-derived Factor Concentrates
    • Factor VIII
    • Factor IX
  • Recombinant Factor Concentrates
    • Factor VIII
    • Factor VII
    • Factor IX
• Desmopressin & Fibrin Sealants
• Gene Therapy & Monoclonal Antibodies

Regional Analysis

North America led the hemophilia market in 2023, with a share of 45%. The region's established market is fueled by a well-developed healthcare infrastructure, early embracement of innovative therapies, and the presence of top pharmaceutical firms. Favorable reimbursement policies and government support for hemophilia treatment have also fueled market growth.

The Asia-Pacific market is expected to witness the highest growth during the forecast period. The rising incidence of hemophilia, increasing awareness, and better healthcare infrastructure in nations like China and India are major drivers of regional growth. In addition, increased research and development investments, as well as increasing access to new therapies, are anticipated to drive market growth in Asia-Pacific.

Recent Developments

• December 2024 – The FDA approved Novo Nordisk's Alhemo (concizumab), a subcutaneous medication for hemophilia A and B patients with inhibitors, offering a new alternative for decreasing bleeding episodes.
• October 2024 – Pfizer got FDA approval for Hympavzi (marstacimab), the first once-weekly therapy for hemophilia A and B with or without inhibitors, providing a more convenient dosing regimen.
• April 2024 – The FDA approved Pfizer's Beqvez (fidanacogene elaparvovec), a one-time gene therapy for hemophilia B, a milestone in long-term treatment options.

Statistical Insights and Trends Reporting

• Hemophilia A affects approximately 1 in 5,000 male births, while Hemophilia B occurs in 1 in 25,000 male births worldwide.
• Increasing diagnosis rates and better screening programs have contributed to higher reported prevalence.
• 60% of hemophilia patients in developed regions have adopted prophylaxis treatment, reducing the frequency of bleeding episodes.
• Non-factor therapies, such as monoclonal antibodies, are gaining traction due to their long-acting benefits.
• Following recent approvals, 15% of eligible hemophilia patients have opted for gene therapy.
• Adoption is expected to increase as long-term efficacy data continues to support its benefits.

Buy a Single-User PDF of Hemophilia Market Analysis & Outlook Report 2024-2032@

Table of Contents – Major Key Points

1. Introduction

2. Executive Summary

3. Research Methodology

4. Market Dynamics Impact Analysis

5. Statistical Insights and Trends Reporting

5.1 Incidence and Prevalence (2023)

5.2 Treatment Adoption Trends (2023), by Region

5.5 Healthcare Spending on Hemophilia (2023)

5.6 Therapeutic Advancements and Innovation Trends

6. Competitive Landscape

7. Hemophilia Market by Type

8. Hemophilia Market by Treatment Type

9. Hemophilia Market by Distribution Channel

10. Hemophilia Market by Therapy

11. Regional Analysis

12. Company Profiles

13. Use Cases and Best Practices

14. Conclusion

Access Complete Report Details of Hemophilia Market Analysis & Outlook 2024-2032@

[For more information or need any customization research mail us at ...]

About Us:

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)

MENAFN12032025004107003653ID1109306708